Citations

Clear

16280 citation(s) found for "Yu, David".

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi -NT in Patients with Advanced Solid Tumors
Nelson, Blessie Elizabeth , Jankú, Filip , Fu, Siqing , Dumbrava, Ecaterina E. , Hong, David S. , Karp, Daniel D. , Naing, Aung , Tsimberidou, Apostolia M. , Murthy, Ravi , Sheth, Rahul A. , Amaria, Rodabe N. , Carapanceanu, Nicoleta, Singh, Mahendra Pal , Carapanceanu, Valentin, Pezeshki, Abdulmohammad , Leontovich, Alexey A. , Kreider, Brent L. , Tung, David, Varterasian, Mary , Khazaie, Khashayarsha , Piha‐Paul, Sarina A. , Rodon, Jordi , Tsimberidou, Apostolia Maria , Murthy, Ravi , Sheth, Rahul A , Amaria, Rodabe N , Conley, Anthony P , Damodaran, Senthil , Raghav, Kanwal P S , Carapanceanu, Nicoleta , Singh, Mahendra Pal , Carapanceanu, Valentin , Pezeshki, Abdulmohammad , Kreider, Brent , Tung, David , Varterasian, Mary , Khazaie, Khashayarsha , Piha-Paul, Sarina A , Hong, David S , Conley, Anthony P. , Raghav, Kanwal

Mayo Clinic

Clinical Cancer Research | July 11, 2025 | Volume: 31 | Issue: 18 | Pages: 3864-3875

10.1158/1078-0432.ccr-24-3952 | PMID 40643985 Get It

Abstract Purpose: Intratumoral injection of Clostridium novyi-nontoxic (C. novyi-NT), lacking alpha-toxin, germinates and subsequently replicates in the tumor hypoxic regions, causing cell lysis and inflammation. This phase Ib study investigated the safety and synergistic effects of pembrolizumab and C. novyi-NT in advanced solid tumors. Patients and Methods: Patients with injectable solid tumors received one intratumoral C. novyi-NT injection (day 8) across four dose cohorts (3 × 104 to 100 × 104 spores) with pembrolizumab (200 mg intravenously every 3 weeks, day 0–24 months). Sixteen patients were enrolled with a median age of 62.5 years, and the most common tumor types were breast cancer and melanoma. Results: The combination therapy demonstrated a manageable safety profile, with one grade 3 dose-limiting toxicity of abscess formation and the remainder of treatment-related adverse events in ≥10% of patients being grade 1 or 2 injection site reaction (25%), pyrexia (19%), pruritus (13%), leukopenia (13%), and anemia (13%). The maximum tolerated dose was determined to be pembrolizumab intravenously at 200 mg every 3 weeks and a single dose of 100 × 104C.novyi-NT spores intratumorally on day 8. The confirmed overall objective response rate of 25% was observed among four patients with nonkeratinizing undifferentiated nasopharyngeal squamous carcinoma, human papilloma virus–positive squamous cell carcinoma of the base of the tongue, vulvar melanoma, and chordoma. Among these patients, we obtained three partial responses and one complete response. The median duration of the response was 10.93 months, and stable disease was observed in 69% of patients. Conclusions: This study highlights the potential of the C. novyi-NT and pembrolizumab combination as a promising therapeutic strategy for treatment-refractory solid tumors.
Lifetime Risk of First Symptomatic ICH or Seizure in Familial Cerebral Cavernous Malformations
Dammann, Philipp , Santos, Alejandro N. , Mavarani, Laven , Chabriat, Hugues , Croft, Jacob , Renteria, Mellisa, Jang, David, Zhang, Jun , Li, Da , Weng, Jiancong , Pilz, Robin A. , Felbor, Ute , Steinberg, Gary K. , Bervini, David , Raabe, Andreas , Rosales, Julieta , Rieß, Christoph , Karadachi, Hannah, Li, Yan , Köhrmann, Martin, Frank, Benedikt , Schmidt, Börge , Overstijns, Manou , Fung, Christian , Zafar, Atif , Nelson, Jeffrey , Zabramski, Joseph M. , Akers, Amy , Kim, Helen , Guey, Stéphanie , Chabriat, Hugues , Herve, Dominique , Zhang, Jun , Weng, Jian-Cong , Rath, Matthias , Steinberg, Gary K , Bervini, David , Rauschenbach, Laurèl , Jabbarli, Ramazan , Beck, Jürgen , Fung, Christian , Al-Shahi Salman, Rustam , Flemming, Kelly D , Lanzino, Giuseppe , Morrison, Leslie , Kim, Helen , Sure, Ulrich , Karadachi, Hanah Hadice , Santos, Alejandro N. , Guey, Stéphanie , Wu, Zhenhua , Petracca, Antonio , Fusco, Carmela , D’Agruma, Leonardo , Castori, Marco , Gu, Jing , Goldberg, Johannes , Cervio, Andrés , Villamil, Facundo , Rauschenbach, Laurèl , Oppong, Marvin Darkwah , Ahmadipour, Yahya , Wrede, Karsten Henning , Jabbarli, Ramazan , Deuschl, Cornelius , Piedade, Guilherme Santos , Wälchli, Thomas , Salman, Rustam Al‐Shahi , Flemming, Kelly D. , Lanzino, Giuseppe , Weinsheimer, Shantel , McCulloch, Charles E. , Sure, Ulrich

Mayo Clinic

Neurology | July 10, 2025 | Volume: 105 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000213798 | PMID 40638881 Get It

Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Swarm, Robert A., Youngwerth, Jeanie, Anițescu, Magdalena , Are, Madhuri , Buga, Sorin , Butler, Taylor, Cleary, James F. , Copenhaver, David, Coyne, Christopher , Craig, David S., Finnes, Heidi D. , Greenlee, Heather , Gupta, Mona, Hansen, Eric, Javed, Saba , Kandil, Enas , Mackey, Sean , McGrath, Kathryn, Moryl, Natalie , Nesbit, Suzanne , Noonan, Michael , Norris, Joseph, Pršić, Elizabeth , Rabow, Michael W. , Rickerson, Elizabeth , Sindt, Jill E. , Vorenkamp, Kevin E. , Cunningham, Rebecca, Gurski, Lisa A., Jones, Frankie, Finnes, Heidi, Agne, Julia L. , Butler, Taylor, Chwistek, Marcin , Gupta, Mona, Javed, Saba , McDonald, Andrew, Noonan, Michael, Paice, Judith A. , SMITH, MICHAEL D. , Bruce, Justine Y. , Yoo, Sun

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 10, 2025 | Volume: 23 | Issue: 7 | Pages: No page available

10.6004/jnccn.2025.0032 | PMID 40639401 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Adult Cancer Pain provide recommendations for the comprehensive management of pain in patients with cancer. This article will focus on methods for screening for pain, safe and appropriate prescription of opioid and miscellaneous analgesics, and the optimization of nonpharmacologic interventions including integrative and interventional strategies for treatment of cancer-related pain. Additionally, the NCCN Guidelines discuss methods for the safe reduction of opioids when appropriate, as well as techniques for encouraging the judicious use of opioids. The complete version of the NCCN Guidelines for Adult Cancer Pain addresses additional issues that are not covered here, including management of pain during a pain crisis, management of procedure-related pain and anxiety, pain management for cancer survivors, and the use of nonopioid and adjuvant analgesics for cancer-related pain.
Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance
Weigand, Stephen D. , Wiste, Heather J. , Graff‐Radford, Jonathan, Graff‐Radford, Neill R., Petersen, Ronald C., Jack, Clifford R. , Lowe, Val J. , Fields, Julie A. , Neth, Bryan J. , Day, Gregory S. , Kantarci, Kejal, Bornhorst, Joshua A. , Initiative, and the Alzheimer's Disease Neuroimaging, Kantarci, Kejal , Neth, Byran J. , Jack, Clifford R , Kantarci, Kejal , Day, Gregory S , Bornhorst, Joshua , Knopman, David S. , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Petersen, Ronald C. , Boeve, Bradley F. , Machulda, Mary M. , Ramanan, Vijay K. , Botha, Hugo , McCarter, Stuart J. , Jones, David T. , Algeciras‐Schimnich, Alicia , Johnson, Derek R. , Initiative, and the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | July 9, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70468 | PMID 40631430 Get It

Abstract INTRODUCTION When cerebrospinal fluid (CSF) and positron emission tomography (PET) measurements for amyloid‐beta‐peptide (Aβ) related pathology are discordant, therapeutic decision‐making becomes uncertain. METHODS Using data from patients with mild cognitive impairment ( n = 541) from the Alzheimer's Disease Neuroimaging Initiative, we examined baseline characteristics and longitudinal clinical outcomes in persons grouped according to normal/abnormal Aβ via concurrent CSF and PET determinations using standard cutpoints. RESULTS Discordant groups for brain Aβ status (CSF+/PET− and CSF−/PET+) each represented about 5% of the mild cognitive impairment (MCI) population. Longitudinally, neither discordant group declined more than the CSF−/PET− group on either a memory measure or the Clinical Dementia Rating Sum of Boxes scores over a median 4 years of observation, while the CSF+/PET+ group exhibited worsening on both measures. DISCUSSION In contrast to the clinical decline observed in the CSF+/PET+ group, persons with MCI and CSF+/PET− or CSF−/PET+ brain amyloid patterns did not exhibit incipient decline. Highlights Discrepant abnormal cerebrospinal fluid (CSF) and positron emission tomography (PET) brain amyloid indicators are uncommon in mild cognitive impairment (MCI). CSF‐PET discrepant persons with MCI tend to have less abnormal values initially. CSF‐PET discrepant persons with MCI have a benign prognosis at 4 years.
A Patient With Risk Factors for Barrett’s Esophagus (BE) Undergoes Screening With a Cellular Collection Device
Bartram, Alexander , O’Donovan, Maria , Fitzgerald, Rebecca C. , Katzka, David A.

Mayo Clinic

Foregut: The Journal of the American Foregut Society | July 9, 2025 | Volume: 5 | Issue: 3 | Pages: 300-305

10.1177/26345161251354937 Get It

Minimally invasive esophageal cellular collection devices such as the Capsule Sponge may offer the potential for targeted screening of high-risk patients. The capsule sponge has been shown to be a safe, accurate and effective means of detecting Barrett’s esophagus. Here, we explore two potential real-life scenarios that could occur in a future screening or case finding programme. Firstly, when the capsule sponge test result is positive but confirmatory endoscopy demonstrates <1cm of columnar epithelium and secondly when subsequent endoscopy identifies gastric intestinal neoplasia. We discuss the clinical implication of the result and suggest how these patients could potentially be followed up in the future.
Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta‐Registry
Jose, Arun , Yogeswaran, Athiththan , Fünderich, Meike , Kiely, David G. , Sweatt, Andrew J. , Zamanian, Roham T. , Mouawad, Antoine , Balasubramanian, Aparna , Wilkins, Martin R. , Olschewski, Horst , Eichstaedt, Christina A. , Sіrenko, Yu.M. , Majeed, Raphael W. , Wilhelm, Jochen , Tello, Khodr , Elwing, Jean , Seeger, Werner , Thenappan, Thenappan , Ghouleh, Imad Al , Fuenderich, Meike , Kiely, David , Mouawad, Antoine , Wilkins, Martin , Sahay, Sandeep , Giannakoulas, George , Cajigas, Héctor , Frantz, Robert P , Ghio, Stefano , Majeed, Raphael W , Tello, Khodr , Elwing, Jean M , Seeger, Werner , Olschewski, Horst , Thenappan, Thenappan , Jose, Arun , Yogeswaran, Athiththan , Balasubramanian, Aparna , Hassoun, Paul M. , Lawrie, Allan , Howard, Luke , Sahay, Sandeep , Kovács, Gábor , Saleh, Khaled Musa Mohammad , Sabbour, Hani Mohamed , Grünig, Ekkehard , Arvanitaki, Alexandra , Torbas, O.O. , Frantz, Robert P. , Scelsi, Laura , Ghio, Stefano , Ghofrani, Hossein Ardeschir , Grimminger, Friedrich

Mayo Clinic

Pulmonary Circulation | July 9, 2025 | Volume: 15 | Issue: 3 | Pages: No page available

10.1002/pul2.70121 | PMID 40636151 Get It

ABSTRACTPortopulmonary hypertension (PoPH), a type of pulmonary arterial hypertension (PAH) in patients with liver disease, is associated with high morbidity and mortality. The relationship between cardiopulmonary hemodynamics, PAH therapy, and survival in PoPH remains unclear. We performed a retrospective cohort study of PoPH patients from the international pulmonary hypertension (PH) meta‐registry, PVRI GoDeep. PAH was defined by a mean pulmonary arterial pressure > 20 mmHg, pulmonary arterial wedge pressure ≤ 15 mmHg, and a pulmonary vascular resistance (PVR) > 2 Wood Units. PoPH diagnoses were assigned by each center's PH specialist based on international guidelines at the time of enrollment. 246 incident PoPH patients met eligibility criteria and were included in the analysis, equally split between males (51%) and females (49%), with a median age of 54 years. When compared to both patients with IPAH and those with other subtypes of PAH (not classified as PoPH or IPAH), those with PoPH had significantly lower 5‐year survival rates (46% vs. 68% vs. 65%, log‐rank p < 0.001). Amongst the PoPH patients, however, there was no significant difference in 5‐year survival when dichotomized by disease severity, either by a PVR of 5 Wood Units or a CI of 2.5 L/min/m2. Treatment of the PoPH patients with PAH‐targeted therapies was associated with significantly higher 5‐year survival rates compared to those not receiving such treatments, as shown by Kaplan–Meier analysis. This survival benefit was observed for PDE5i (50% vs. 34%, log‐rank p = 0.029), ERA (58% vs. 34%, log‐rank p < 0.001), and the combination of PDE5i and/or ERA (51% vs. 22%, log‐rank p < 0.001), as well as any PAH‐targeting treatment (50% vs. 26%, log‐rank p = 0.007). Corresponding survival advantage was noted when including only PoPH patients with MELD Score ≥ 13. PoPH is a disease with significantly worse long‐term survival than other PAH subtypes, but targeted PAH therapy is associated with a robust survival benefit. Survival did not differ across high‐risk PVR and cardiac index thresholds, suggesting the factors that influence prognosis and survival in PoPH may be unique as compared to other PAH subtypes, and warrant further investigation.
The Evolving Application of Radiation Segmentectomy for the Treatment of Hepatic Malignancy
Lewandowski, Robert J. , Serhal, Muhamad , Padia, Siddharth A. , Kim, Edward , Brown, Daniel B. , Tabori, N., Toskich, Beau B. , Toskich, Beau , Padia, Siddarth A , Kim, Edward

Mayo Clinic

Radiology | July 8, 2025 | Volume: 316 | Issue: 1 | Pages: No page available

10.1148/radiol.240333 | PMID 40626876 Get It

Radiation segmentectomy is a dynamic image-guided therapy for hepatic malignancies that uses yttrium 90 transarterial radioembolization to deliver high radiation doses to targeted hepatic segments, achieving high and sustained response rates.
Supporting the Deceased, Their Families, and Their Communities – Part 2: Practical Guidance for Building an Office of Decedent Affairs
Chambers, Meagan , Bartholow, Tanner, Parker, Zachary T., Peters, Kristina, Reichard, R. Ross , Tigard, Charles, Hooper, Jody E. , Benson, Paul , Davis, Ronnie, Cool, Robert, Beglarian, Ben, Mount, Sharon , Jackson, Nicole R. , Marshall, Desiree A. , Harcourt, Lisbeth, Wiley, LaTresa E., Comstock, Jessica, Hyland, Courtney, Harper, Holly , Priemer, David S. , Rapkiewicz, Amy , Rojiani, Amyn M. , Sanchez, Harold, Parker, Zachary T., Peters, Kristina, Luthringer, Daniel , Davis, Ronnie, Scherpelz, Kathryn P. , Sinard, John H. , Chen, Sonja

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 8, 2025 | Volume: 149 | Issue: 12 | Pages: 1077-1083

10.5858/arpa.2025-0094-oa | PMID 40626859 Get It

Context.— After-death care can be complicated and time-consuming for clinical staff, and frustrating for bereaved families. Delays and errors can have damaging legal and reputational consequences for hospitals. Offices of Decedent Affairs (ODAs) have been proposed as a solution, and their potential benefits have been described in several single institution reports. The literature lacks a contemporary and comprehensive review of existing ODAs and their approaches. Objective.— To describe the process of establishing a new ODA and to provide a snapshot of the spectrum of structure, function, and impact of existing ODAs in the United States. Design.— A survey was administered to 11 established ODAs spread across the continental United States. Programs were identified through the College of American Pathologists Autopsy Committee and a Medical Autopsy Listserv. Results.— Eleven ODAs returned the survey, representing more than 190 cumulative years of experience in decedent care in the hospital setting (median, 10 years). There was a wide range in staffing (both staff size and background) as well as scope of services offered. The median ratio of hospital deaths to full-time equivalent (FTE) staffing was 360 deaths per FTE. Respondents reported that ODAs unburden clinical providers and facilitate decedent management. Some respondents reported a quicker turnover of hospital beds and shorter intervals between pronouncement of death and autopsy. ODAs increased autopsy rates when the autopsy services were part of the ODA. Conclusions.— This survey provides practical information for hospitals considering establishing a new ODA and useful benchmarks for existing ODA programs.
Supporting the Deceased, Their Families, and Their Communities – Part 1: Why Establish an Office of Decedent Affairs
Chambers, Meagan , Bartholow, Tanner, Parker, Zachary T., Peters, Kristina, Reichard, R. Ross , Tigard, Charles, Hooper, Jody E. , Benson, Paul , Davis, Ronnie, Cool, Robert, Beglarian, Ben, Mount, Sharon , Jackson, Nicole R. , Marshall, Desiree A. , Harcourt, Lisbeth, Wiley, LaTresa E., Comstock, Jessica, Hyland, Courtney, Harper, Holly , Priemer, David S. , Rapkiewicz, Amy , Rojiani, Amyn M. , Sanchez, Harold, Parker, Zachary T., Peters, Kristina, Luthringer, Daniel , Davis, Ronnie, Scherpelz, Kathryn P. , Sinard, John H. , Chen, Sonja

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 8, 2025 | Volume: 149 | Issue: 12 | Pages: 1072-1076

10.5858/arpa.2025-0090-oa | PMID 40626861 Get It

Context.— Decedent Affairs Offices and Programs can serve as an avenue to assist medical centers in facilitating efficient and comprehensive decedent management, despite a paucity of literature on their roles, establishment, and efficacy. Objective.— To characterize the motivations and rationales for establishing Decedent Affairs Offices. Design.— A survey was administered to 11 established Decedent Affairs Offices/Programs, identified through the College of American Pathologists Autopsy Committee and a Medical Autopsy Listserv. The questions comprehensively cover establishment, operations, and outcomes data available by institution. Results.— Survey respondents reported the rationale for starting their programs and the benefits such offices can have. Conclusions.— Decedent Affairs Offices and Programs provide a useful option to medical centers to navigate the increasingly complex task of comprehensive decedent management. The present survey helps to delineate the similarities and differences between these programs at 11 institutions, to aid nascent programs in their establishment and growth over time.
Sex‐Dependent Circadian Rhythm Impact on Murine Gastrointestinal Transit
Bellampalli, Shreya S. , Fonar, Gennadiy , Grynyshyn, Michael, Mercado‐Perez, Arnaldo , Farrugia, Gianrico , Matveyenko, Aleksey V. , Linden, David R. , Beyder, Arthur , Muchhala, Karan H, Linden, D R , Beyder, Arthur , Muchhala, Karan H.

Mayo Clinic

Neurogastroenterology & Motility | July 8, 2025 | Volume: 37 | Issue: 12 | Pages: No page available

10.1111/nmo.70114 | PMID 40626374 Get It

ABSTRACT Background The circadian rhythm regulates gastrointestinal motility. In humans and preclinical models, such as rodents, whole gut transit (WGT) is slower during the rest phase compared to the active phase. Investigators typically study GI transit in rodents during the day, which is their rest phase, rather than during the night, which is their active phase. A circadian rhythm reversal in which mice are in a dark room during the working day (reverse light) allows studies on nocturnal animals during their active phase and has been previously shown to reduce WGT time. GI motility is often disrupted in individuals with disorders of gut–brain interaction (DGBI), which are female predominant. However, the effect of circadian rhythm on regional transit and sex dependence of the differences is not known, as most motility studies looking at circadian rhythm reversal are done in male mice. Methods We tested C57BL/6 wild‐type male and female mice in rest (12 h of light during the day) and active (reverse cycle for 2 weeks: 12 h of dark during the day) phases. We noted female estrous cycle by visual inspection. We performed carmine WGT by monitoring time‐lapse videos of pellet production. We performed fluorescence imaging of excised intestines 30 min after gavage to assess percent fluorescence for each GI region and then examined small intestinal transit (SIT) by measuring geometric center and leading edge. For colonic transit, we monitored bead expulsion time from distal colon to anus. Key Results Compared to rest phase, in the active phase, like male mice, female mice had (1) faster WGT, (2) increased frequency of pellet expulsion in the first 3 h of transit, (3) and greater total pellet production. Both male and female mice in their active phase exhibited (4) more contrast emptied from the stomach and they had (5) further leading edge of fluorescence and (6) geometric center, in SIT, and (7) faster colonic bead expulsion times. There were no significant sex differences in the active phase of WGT. In SIT, male mice had further leading edge in the rest phase than female mice, but this difference was not seen in the active phase, and in colonic transit, male mice in both the active and rest phases had faster bead expulsion than female mice. Conclusions Mice in the active phase have faster regional transit in small and large bowel than mice in the rest phase that collectively contributes to faster WGT times in the active phase of both male and female mice. These findings highlight the importance of circadian biology in sex‐dependent rodent GI transit.